{"organizations": [], "uuid": "594da62e87668ea04c8e9a1b65fa11cfd44ba0ff", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "in.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/INhealth\r", "section_title": "Reuters: Health", "url": "https://in.reuters.com/article/us-novo-nordisk-diabetes/novo-nordisks-oral-diabetes-drug-beats-jardiance-in-study-idINKCN1IU28V", "country": "US", "domain_rank": 408, "title": "Novo Nordisk's oral diabetes drug beats Jardiance in study", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-29T19:57:00.000+03:00", "replies_count": 0, "uuid": "594da62e87668ea04c8e9a1b65fa11cfd44ba0ff"}, "author": "", "url": "https://in.reuters.com/article/us-novo-nordisk-diabetes/novo-nordisks-oral-diabetes-drug-beats-jardiance-in-study-idINKCN1IU28V", "ord_in_thread": 0, "title": "Novo Nordisk's oral diabetes drug beats Jardiance in study", "locations": [], "entities": {"persons": [{"name": "jardiance", "sentiment": "negative"}, {"name": "mads krogsgaard thomsen", "sentiment": "none"}, {"name": "mark heinrich", "sentiment": "none"}, {"name": "ben hirschler", "sentiment": "none"}], "locations": [{"name": "london", "sentiment": "none"}], "organizations": [{"name": "novo nordisk", "sentiment": "negative"}, {"name": "eli lilly", "sentiment": "none"}, {"name": "boehringer ingelheim", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "novo", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "LONDON (Reuters) - An experimental diabetes pill from Novo Nordisk proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim’s established Jardiance in a clinical study, the Danish drugmaker said on Tuesday.\nThe success of oral semaglutide in the Phase III trial is a boost for a medicine seen as important for ensuring the group’s long-term growth in a highly competitive diabetes market.\nThe once-daily pill, which Novo hopes to launch in 2020, belongs to a blockbuster class of treatments known as GLP-1s that stimulate insulin production. So far, all have been injections and a pill would offer a step-change in convenience.\nMads Krogsgaard Thomsen, Novo’s chief science officer, said the positive results from the so-called PIONEER 2 trial were “an important milestone” in the clinical development of oral semaglutide.\nReporting by Ben Hirschler; Editing by Mark Heinrich\n ", "external_links": [], "published": "2018-05-29T19:57:00.000+03:00", "crawled": "2018-05-29T20:33:56.001+03:00", "highlightTitle": ""}